Pharmacogenetics of Psychotropic Drugs

Pharmacogenetics and pharmacogenomics are areas of rapidly growing importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs; it reviews advances in the field and describes the findings that have already emerged.

Coverage extends to antipsychotics, antidepressants, mood-stabilizing, cognitive-enhancing, and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider the impact of pharmacogenetics on the biotechnology and pharmaceutical industries.

This book defines the young field of pharmacogenetics as it applies to psychotropic drugs and is, therefore, an essential reference for all clinicians and researchers working in this field.

Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah-Hebrew University Medical Center in Jerusalem. He is Director of the National Institute for Psychobiology in Israel, and Editor-in-Chief of the International Journal of Neuropsychopharmacology.
# Contents

*List of contributors*  page viii

## Part I Introduction

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Genes and psychopharmacology: exploring the interface</td>
<td>Bernard Lerer</td>
<td>3</td>
</tr>
</tbody>
</table>

## Part II Clinical background and research design

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>From pharmacogenetics to pharmacogenomics of psychotropic drug response</td>
<td>Anil K. Malhotra</td>
<td>21</td>
</tr>
<tr>
<td>3</td>
<td>Neuropsychopharmacology: the interface between genes and psychiatric nosology</td>
<td>Thomas A. Ban</td>
<td>36</td>
</tr>
<tr>
<td>4</td>
<td>Methodological issues in psychopharmacogenetics</td>
<td>Sheldon H. Preskorn</td>
<td>57</td>
</tr>
<tr>
<td>5</td>
<td>Statistical approaches in psychopharmacogenetics</td>
<td>Fabio Macciardi</td>
<td>72</td>
</tr>
</tbody>
</table>

## Part III Molecular background

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>The psychopharmacogenetic–neurodevelopmental interface in serotonergic gene pathways</td>
<td>K. Peter Lesch, Jens Benninghoff, and Angelika Schmitt</td>
<td>95</td>
</tr>
</tbody>
</table>
Contents

7 RNA processing regulation and interindividual variation 127
  Colleen M. Niswender and Linda K. Hutchinson

Part IV Pharmacokinetics

8 Pharmacogenetics of psychotropic drug metabolism 157
  Vural Ozdemir, Angela D.M. Kashuba, Vincenzo S. Basile, and James L. Kennedy

9 Pharmacogenetics of chiral psychotropic drugs 181
  Pierre Baumann and Chin B. Eap

Part V Specific psychotropic drugs and disorders

10 Clozapine response and genetic variation in neurotransmitter receptor targets 217
  David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama, and Robert W. Kerwin

11 Genetic factors underlying drug-induced tardive dyskinesia 245
  Ronnen H. Segman and Bernard Lerer

12 Functional gene-linked polymorphic regions in pharmacogenetics 267
  Marco Catalano

13 Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders 283
  Emanuela Mundo and James L. Kennedy

14 Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex 300
  Smita A. Pandit, Spilios V. Argyropoulos, Patrick G. Kehoe, and David J. Nutt

15 Genetic factors and long-term prophylaxis in bipolar disorder 320
  Martin Alda

16 Genetic influences on responsiveness to anticonvulsant drugs 333
  Thomas N. Ferraro

17 Apolipoprotein E as a marker in the treatment of Alzheimer’s disease 360
  Keith Schappert, Pierre Sevigny, and Judes Poirier
vii  Contents

18  Genetic variation and drug dependence risk factors  372
    Joel Gelernter and Henry Kranzler

Part VI  Pharmacogenetics and brain imaging

19  Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia  391
    Steven G. Potkin, James L. Kennedy, and Vincenzo S. Basile

Part VII  Industry perspectives

20  Pharmacogenetics in psychotropic drug discovery and development  401
    William Z. Potter, AnnCatherine Van Lone, and Larry Altstiel

21  High-throughput single nucleotide polymorphism genotyping  420
    Anne Shalom and Ariel Darvasi

Index  439
Contributors

Martin Alda
Department of Psychiatry, Dalhousie University, Abbie J. Lane Building, 5909 Jubilee Rd, Halifax, Nova Scotia, B3H 2E2, Canada

Larry Altsteil
Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, NJ 07033-1300, USA

Spilios V. Argyropoulos
Psychopharmacology Unit, University of Bristol, University Walk, Bristol BS8 1TD, UK

Maria J. Arranz
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Thomas A. Ban
Vanderbilt University, Nashville, TN, USA

Vincenzo S. Basile
Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

Pierre Baumann
Department Universitaire de Psychiatrie Adulte, Adulte Hopital de Cery, CH-1008 Prilly, Switzerland

Jens Benninghoff
Department of Psychiatry, University of Wurzburg, Fuchsleinstr. 15, 97080 Wurzburg, Germany

Marco Catalano
IRCCS H. San Raffaele, Department of Neuropsychiatric Sciences, Milan, Italy

David A. Collier
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Ariel Darvasi
The Life Sciences Institute, The Hebrew University of Jerusalem and IDgene Pharmaceuticals, Jerusalem 91904, Israel

Chin B. Eap
Department Universitaire de Psychiatrie Adulte, Adulte Hopital de Cery, CH-1008 Prilly, Switzerland

Thomas N. Ferraro
Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, 415 Curie Blvd, Philadelphia, PA 19104, USA
List of contributors

Joel Gelernter
Department of Psychiatry, Yale University
School of Medicine, New Haven, CT 06516, USA

Linda K. Hutchinson
Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA

Angela D.M. Kashuba
School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

Patrick G. Kehoe
Psychopharmacology Unit, University of Bristol, University Walk, Bristol, BS8 1TD, UK

James L. Kennedy
Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

Robert W. Kerwin
Institute of Psychiatry, De Crespiggy Park, Denmark Hill, London SE5 8AF, UK

Henry Kranzler
Department of Psychiatry, University of Connecticut, School of Medicine, Farmington, CT, USA

Bernard Lerer
Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah-Hebrew University Medical Center, Ein Karem, Jerusalem 91120, Israel

K. Peter Lesch
Department of Psychiatry, University of Wurzburg, Fuchseleinstr. 15, 97080 Wurzburg, Germany

Fabio Macciardi
Unit of Biostatistics and Genetic Epidemiology, Neurogenetics Section, Clarke Division, Center for Addiction and Mental Health, R-32, 250 College Street, Toronto, Ontario, MST 1R8, Canada

Anil K. Malhotra
Unit of Molecular Psychiatry, Hillside Hospital, 75–59 263rd St, Glen Oaks, NY 11004, USA

Dalu Mancama
Institute of Psychiatry, De Crespiggy Park, Denmark Hill, London SE5 8AF, UK

Emanuela Mundo
Department of Psychiatry, University of Wurzburg, Fuchsleinstr. 15, 97080 Wurzburg, Germany

Janet Munro
Institute of Psychiatry, De Crespiggy Park, Denmark Hill, London SE5 8AF, UK

Colleen M. Niswender
Department of Pharmacology, University of Washington, Seattle, WA 98195, USA

David J. Nutt
Psychopharmacology Unit, University of Bristol, University Walk, Bristol, BS8 1TD, UK

Sarah Osborne
Institute of Psychiatry, De Crespiggy Park, Denmark Hill, London SE5 8AF, UK

Vural Ozdemir
Department of Pharmacogenomics, Drug Discovery Division, R.W. Johnson Pharmaceutical Research Institute, Route 202 South, #1000 OMP Building, Raritan, NJ 08869, USA
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smita A. Pandit</td>
<td>Psychopharmacology Unit, University of Bristol, University Walk, Bristol, BS8 1TD, UK</td>
</tr>
<tr>
<td>Judes Poirier</td>
<td>Center for Studies in Aging, 6875 Blvd. Lasalle, Verdun, Quebec, H4H 1R3, Canada</td>
</tr>
<tr>
<td>Steven G. Potkin</td>
<td>Brain Imaging Center, University of California, Irvine Hall, Irvine, CA 92697–3960, USA</td>
</tr>
<tr>
<td>William Z. Potter</td>
<td>Lilly Research Laboratory, Lilly Corporate Center, Drop Code 0532, Indianapolis, IA 46285, USA</td>
</tr>
<tr>
<td>Sheldon H. Preskorn</td>
<td>Psychiatric Research Institute, University of Kansas, 1100 N. St Francis, Wichita, KS 67214, USA</td>
</tr>
<tr>
<td>Keith Schappert</td>
<td>Mirador DNA Design, Suite 501, 404 McGill St, Montreal, Quebec H2Y 2G1, Canada</td>
</tr>
<tr>
<td>Angelina Schmitt</td>
<td>Department of Psychiatry, University of Wurzburg, Fuchseinstr. 15, 97080 Wurzburg, Germany</td>
</tr>
<tr>
<td>Ronnen H. Segman</td>
<td>Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah-Hebrew University Medical Center, Ein Karem, Jerusalem 91120, Israel</td>
</tr>
<tr>
<td>Pierre Savigny</td>
<td>Mirador DNA Design, Suite 501, 404 McGill St, Montreal, Quebec H2Y 2G1, Canada</td>
</tr>
<tr>
<td>Anne Shalom</td>
<td>The Life Sciences Institute, The Hebrew University of Jerusalem, Israel</td>
</tr>
<tr>
<td>AnnCatherine Van Lone</td>
<td>Lilly Research Laboratory, Lilly Corporate Center, Drop Code 0532, Indianapolis, IA 46285, USA</td>
</tr>
</tbody>
</table>